O2h Ventures

Monument Therapeutics is a biotechnology company focused on developing drugs for treating serious diseases of the central nervous system. Its innovative approach employs proprietary digital biomarkers to reduce patient heterogeneity, enabling more targeted neuroscience drug development in areas with unmet medical needs.

Atelerix Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2006. It specializes in the storage and transportation of cells and tissues at room temperature, utilizing a patented technology that encapsulates biological products in a natural hydrogel. This innovative approach allows for the safe shipment and storage of viable cells, including suspended cells, planted cells, and stem cells, without the need for cryopreservation or harmful supplements. By protecting cells from biochemical and physical damage, Atelerix enables immediate use of cells and assays upon arrival, enhancing reliability in drug discovery and cell therapy applications. The company's technology contributes to more predictable and effective outcomes in medical and research settings.

Healx is a Cambridge, United Kingdom-based biotechnology company that focuses on treating rare diseases. It leverages artificial intelligence and machine learning to accelerate drug discovery and repurposing, pairing computational insights with pharmacology expertise and patient engagement to match therapies to specific diseases. The company uses generative AI to identify new drug candidates and repurpose existing medications with known safety profiles, aiming to lower development risk and cost while addressing unmet needs of patients with rare diseases.

ViaNautis specializes in the development of innovative medications that effectively cross biological barriers, including the blood-brain barrier. The company employs its proprietary PolyNaut technology, a versatile nano-engineered polymer system designed for intracellular delivery. This technology allows for the encapsulation of various therapeutic modalities into polymer nanovesicles, which can selectively target different tissues and cell types. By facilitating the penetration of these barriers, ViaNautis enhances the therapeutic efficacy of the encapsulated molecules, providing significant benefits in medication delivery and treatment outcomes. Collaborating with multiple partners, the company aims to revolutionize how medications are developed and delivered, particularly in addressing challenging medical conditions.

Pencil Biosciences is focused on advancing gene-editing technology through the development of a novel, programmable genome-modulation platform. This innovative approach seeks to address the limitations of existing gene-editing technologies, providing new therapeutic options for patients with rare diseases. By enhancing the precision and efficacy of genome modulation, Pencil Biosciences aims to facilitate a wide range of applications in the medical field, ultimately supporting healthcare professionals in overcoming the challenges associated with traditional gene-editing methods.

Kuano Ltd is a London-based company that specializes in providing quantum and artificial intelligence solutions for molecular design, particularly in the fields of drug discovery and development. Founded in 2020, Kuano has developed a unique discovery platform that integrates quantum simulation with AI-led chemistry, enabling the design of effective inhibitors by analyzing the mechanisms of target enzymes. This innovative approach allows for faster and more efficient development of drug candidates, enhancing the quality of new pharmaceuticals while simultaneously reducing the time required for discovery. The company's solutions are applicable across various sectors, including pharmaceuticals, crop protection, and industrial chemistry.

PharmEnable Limited is a drug discovery company based in Cambridge, United Kingdom, that specializes in the design of small molecule drugs through the integration of medicinal chemistry and artificial intelligence computational methods. Established in 2016, the company has created a rapid and cost-effective approach to identify superior chemical starting points, thereby facilitating the discovery of essential new medicines.

Founded in 2016, Five Alarm Bio is a biotechnology company based in Cambridge, UK. It focuses on drug discovery to develop anti-aging therapies using a small molecule approach, aiming to enhance the body's defenses against aging-related damage and diseases.

Founded in 2016, Qkine is a biotechnology company based in Cambridge, UK. It specializes in manufacturing high-purity, animal-free growth factors, cytokines, and other complex proteins for life science applications, including stem cell culture, organoid research, and regenerative medicine.

Alevin Therapeutics focuses on developing safe and effective medicines for patients with life-threatening diseases. Its primary focus is on targeted integrin therapies for high-need clinical areas such as fibrosis, including idiopathic pulmonary fibrosis, liver and kidney disease, and cancer.

CardiaTec is a digital biotechnology company focused on revolutionizing cardiovascular drug discovery through the integration of artificial intelligence and specialized expertise. The company aims to transform the understanding of cardiovascular disease by developing AI-driven platforms for target identification and novel drug discovery. This approach seeks to provide effective therapeutics for cardiovascular diseases, addressing significant gaps in diagnostics, patient stratification, and treatment options for conditions such as coronary artery disease. By leveraging advanced technology and scientific knowledge, CardiaTec is dedicated to improving healthcare outcomes related to cardiovascular health.

Spirea Ltd is a healthcare technology company based in Harrogate, United Kingdom, focused on developing innovative antibody drug conjugates (ADCs) for cancer treatment. Established in 2015, Spirea has created a smart polymer platform that enhances the controlled delivery of drug combinations, aiming to maximize the clinical efficacy of therapies. The company's flexible approach to ADC design allows for a greater amount of drug payload to be precisely targeted at tumor cells, increasing therapeutic effects while significantly minimizing adverse side effects. This advancement enables healthcare providers to offer well-tolerated treatment options for a variety of cancer types, ultimately improving patient outcomes.

Oxford Drug Design is a biotechnology company focused on developing innovative therapies to combat drug-resistant infections. The company employs advanced methodologies in computer-aided drug discovery, encompassing the entire process from target identification to preclinical studies and formulation. Its multidisciplinary research team integrates breakthroughs in computational chemistry, cheminformatics, mathematics, and cloud computing to enhance drug discovery efforts. The company's flagship platform, DrugFinder, represents a next-generation approach to identifying and developing new antibiotics, particularly targeting challenging diseases with significant unmet medical needs. By leveraging these technologies, Oxford Drug Design aims to provide healthcare professionals with effective treatment options for patients suffering from antibiotic-resistant bacterial infections.

Neurocentrx specializes in developing innovative medicines for neurological conditions. Its focus lies in psychiatric disorders, neurodegenerative diseases, and complex pain management, particularly in cancer and palliative care patients. The company's primary approach involves reformulating existing drugs into new formats to improve patient outcomes.

Xploro is a healthcare platform that uses augmented reality, gameplay, and artificial intelligence to deliver health information to young patients. Its interactive, engaging content empowers patients, reduces stress and anxiety, and improves clinical outcomes.

Neuroute is an AI-driven platform designed to streamline clinical trial patient recruitment. It employs artificial intelligence to create targeted recruitment strategies and campaigns, connecting healthcare professionals with patients more efficiently.

Neuroute is an AI-driven platform designed to streamline clinical trial patient recruitment. It employs artificial intelligence to create targeted recruitment strategies and campaigns, connecting healthcare professionals with patients more efficiently.

Tay Therapeutics is a biotechnology company focused on drug discovery for the treatment of inflammatory conditions, particularly skin diseases. The company is dedicated to developing innovative topical and oral therapies that serve as alternatives to traditional steroid creams, which are commonly prescribed for conditions like psoriasis and eczema. Recognizing the limitations and potential side effects associated with steroid treatments, Tay Therapeutics aims to deliver safe and effective medications that improve patient outcomes. By prioritizing the needs of patients suffering from skin diseases, the company seeks to revolutionize the therapeutic landscape in this area.

AI VIVO develops an AI-based proprietary pharmacology platform that models the dynamic effects of diseases and treatments at the organ level. The platform supports drug discovery and development by applying an organ-level model to improve clinical predictability of novel therapies. It converts biological hypotheses into data representations and translates these data into medical insights, providing an advanced methodology that enables new discoveries in pharmacology and drug development.

Sanome develops clinical decision support software that creates a real-time digital twin of an individual's health. The platform integrates with electronic health records to analyze clinical data and deliver explainable, regulated AI-enabled tools embedded in clinical workflows, helping healthcare providers identify emerging risks earlier and make faster, more accurate decisions as part of a proactive, preventive model of care. By combining artificial intelligence with diverse data streams, including at-home biomarker tests, the system translates information into actionable insights to support early detection and improved patient outcomes.

BiVictriX Therapeutics Ltd. is a drug discovery and development company based in Alderley Edge, United Kingdom, focused on creating bispecific antibody drug conjugates to address unmet medical needs in blood cancer. Established in 2016, the company leverages its proprietary Bi-Cygni technology to develop innovative therapies for various types of cancers, including Acute Myeloid Leukaemia. BiVictriX specializes in oncology and haematological malignancies, offering a range of services that encompass biotherapeutics, immunotherapy, antibody research, and drug development. The company aims to advance its pharmaceutical products through rigorous development processes to improve treatment outcomes for patients with serious medical conditions.

Kuano Ltd is a London-based company that specializes in providing quantum and artificial intelligence solutions for molecular design, particularly in the fields of drug discovery and development. Founded in 2020, Kuano has developed a unique discovery platform that integrates quantum simulation with AI-led chemistry, enabling the design of effective inhibitors by analyzing the mechanisms of target enzymes. This innovative approach allows for faster and more efficient development of drug candidates, enhancing the quality of new pharmaceuticals while simultaneously reducing the time required for discovery. The company's solutions are applicable across various sectors, including pharmaceuticals, crop protection, and industrial chemistry.

Monument Therapeutics is a biotechnology company focused on developing drugs for treating serious diseases of the central nervous system. Its innovative approach employs proprietary digital biomarkers to reduce patient heterogeneity, enabling more targeted neuroscience drug development in areas with unmet medical needs.

ViaNautis specializes in the development of innovative medications that effectively cross biological barriers, including the blood-brain barrier. The company employs its proprietary PolyNaut technology, a versatile nano-engineered polymer system designed for intracellular delivery. This technology allows for the encapsulation of various therapeutic modalities into polymer nanovesicles, which can selectively target different tissues and cell types. By facilitating the penetration of these barriers, ViaNautis enhances the therapeutic efficacy of the encapsulated molecules, providing significant benefits in medication delivery and treatment outcomes. Collaborating with multiple partners, the company aims to revolutionize how medications are developed and delivered, particularly in addressing challenging medical conditions.

Stingray Bio is a biotechnology company focused on developing precision cancer therapeutics by targeting the LMTK3 kinase. The company develops small molecule inhibitors aimed at specific kinase pathways and uses expertise in structural biology, cellular biology, and cancer pharmacology to advance compounds from discovery toward development. By focusing on LMTK3, Stingray Bio seeks to address unmet needs in oncology and enable healthcare providers and drug developers to pursue new treatment options for patients with diverse cancer types.

PhoreMost is a UK-based drug discovery company specializing in identifying new druggable targets for cancer and other diseases. Established in 2014, it develops Site-Seeker, a platform that systematically uncovers druggable sites in the human genome and links them to useful therapeutic functions in live cells.

Spirea Ltd is a healthcare technology company based in Harrogate, United Kingdom, focused on developing innovative antibody drug conjugates (ADCs) for cancer treatment. Established in 2015, Spirea has created a smart polymer platform that enhances the controlled delivery of drug combinations, aiming to maximize the clinical efficacy of therapies. The company's flexible approach to ADC design allows for a greater amount of drug payload to be precisely targeted at tumor cells, increasing therapeutic effects while significantly minimizing adverse side effects. This advancement enables healthcare providers to offer well-tolerated treatment options for a variety of cancer types, ultimately improving patient outcomes.

Turbine Ltd, established in 2015 and headquartered in Budapest, Hungary, specializes in computational biology for cancer drug development. The company's core product is a predictive model that simulates cellular behavior, aiding in the discovery, preclinical testing, and development of cancer therapies. Turbine's platform leverages proprietary Simulated Cell technology and artificial intelligence to identify novel protein targets and precision biomarkers, ultimately enhancing the translation of research into effective patient treatments.

Tay Therapeutics is a biotechnology company focused on drug discovery for the treatment of inflammatory conditions, particularly skin diseases. The company is dedicated to developing innovative topical and oral therapies that serve as alternatives to traditional steroid creams, which are commonly prescribed for conditions like psoriasis and eczema. Recognizing the limitations and potential side effects associated with steroid treatments, Tay Therapeutics aims to deliver safe and effective medications that improve patient outcomes. By prioritizing the needs of patients suffering from skin diseases, the company seeks to revolutionize the therapeutic landscape in this area.

Cortirio is a developer of portable brain imaging technology aimed at improving the diagnosis and treatment of traumatic brain injuries, which are a leading cause of death and disability among individuals under 40. The company designs portable scanners that utilize near-infrared imaging to deliver high-resolution, point-of-care medical imaging. These wearable devices provide critical information throughout the clinical pathway, facilitating automatic analysis and efficient data transfer. By equipping clinicians with rapid and accurate diagnostic tools, Cortirio enhances decision-making processes and improves care for patients suffering from brain injuries and strokes, ultimately aiming to reduce treatment times and prevent long-term disability or death.

Privitar Ltd. is an enterprise software company specializing in privacy-preserving data mining and advanced data anonymization solutions. Founded in 2014 and headquartered in London, the company serves a diverse global client base across North America, Europe, and Asia. Privitar's product suite includes Privitar Publisher, which allows organizations to securely manage and audit data access, and Privitar Lens, which facilitates the creation of privacy-preserving APIs for reporting and analytics. Additionally, its SecureLink system focuses on data de-identification, while the Privitar Data Privacy Platform enhances data utilization while safeguarding sensitive information. The company's technologies enable clients to analyze potentially sensitive data in compliance with regulations such as GDPR, CPRA, and HIPAA, thereby fostering data-driven innovation and maintaining customer privacy across various sectors, including finance, healthcare, telecommunications, and marketing.

Founded in 2016, Qkine is a biotechnology company based in Cambridge, UK. It specializes in manufacturing high-purity, animal-free growth factors, cytokines, and other complex proteins for life science applications, including stem cell culture, organoid research, and regenerative medicine.

Pencil Biosciences is focused on advancing gene-editing technology through the development of a novel, programmable genome-modulation platform. This innovative approach seeks to address the limitations of existing gene-editing technologies, providing new therapeutic options for patients with rare diseases. By enhancing the precision and efficacy of genome modulation, Pencil Biosciences aims to facilitate a wide range of applications in the medical field, ultimately supporting healthcare professionals in overcoming the challenges associated with traditional gene-editing methods.

Neurofenix is a company focused on enhancing rehabilitation for stroke victims through innovative technology. It has developed an upper limb rehabilitation device that aims to make therapy more autonomous, enjoyable, and accessible. This device features a hand-training controller that allows users to engage their impaired hand in interactive video games, transforming traditional rehabilitation exercises into fun and immersive experiences. By providing patients with effective arm and hand therapy both in clinical settings and from the comfort of their homes, Neurofenix seeks to empower stroke survivors in their recovery journeys.

Turbine Ltd, established in 2015 and headquartered in Budapest, Hungary, specializes in computational biology for cancer drug development. The company's core product is a predictive model that simulates cellular behavior, aiding in the discovery, preclinical testing, and development of cancer therapies. Turbine's platform leverages proprietary Simulated Cell technology and artificial intelligence to identify novel protein targets and precision biomarkers, ultimately enhancing the translation of research into effective patient treatments.

Oxford Drug Design is a biotechnology company focused on developing innovative therapies to combat drug-resistant infections. The company employs advanced methodologies in computer-aided drug discovery, encompassing the entire process from target identification to preclinical studies and formulation. Its multidisciplinary research team integrates breakthroughs in computational chemistry, cheminformatics, mathematics, and cloud computing to enhance drug discovery efforts. The company's flagship platform, DrugFinder, represents a next-generation approach to identifying and developing new antibiotics, particularly targeting challenging diseases with significant unmet medical needs. By leveraging these technologies, Oxford Drug Design aims to provide healthcare professionals with effective treatment options for patients suffering from antibiotic-resistant bacterial infections.

Small Pharma Ltd. is a pharmaceutical company based in London, United Kingdom, founded in 2015. The company specializes in developing a rapid-acting antidepressant aimed at treating patients with depression. Small Pharma employs a scalable model of outsourced drug development, leveraging expert intellectual property design to facilitate the transition from academic discovery to commercial products. By assembling specialized teams with proven expertise across essential development disciplines, Small Pharma aims to effectively execute its drug development programs.

ViaNautis specializes in the development of innovative medications that effectively cross biological barriers, including the blood-brain barrier. The company employs its proprietary PolyNaut technology, a versatile nano-engineered polymer system designed for intracellular delivery. This technology allows for the encapsulation of various therapeutic modalities into polymer nanovesicles, which can selectively target different tissues and cell types. By facilitating the penetration of these barriers, ViaNautis enhances the therapeutic efficacy of the encapsulated molecules, providing significant benefits in medication delivery and treatment outcomes. Collaborating with multiple partners, the company aims to revolutionize how medications are developed and delivered, particularly in addressing challenging medical conditions.

Metrion Biosciences Ltd is a contract research organization based in Cambridge, United Kingdom, specializing in drug discovery services. Founded in 2015, the company provides a range of preclinical screening services, with a particular focus on ion channel testing. Its offerings include cardiac safety screening, neuroscience assays, and translational assays, aimed at supporting pharmaceutical and bioscience clients globally. Metrion Biosciences employs highly skilled electrophysiology techniques and offers flexible business models, including fee-for-service and collaborative options. This versatility allows the company to cater to various medicinal chemistry optimization programs, ensuring comprehensive support throughout the drug discovery process.

DeepMatter Group Plc is a big data and analysis company based in Bristol, United Kingdom. The company operates through two segments: DeepMatter and InfoChem. It has developed the DigitalGlassware platform, which enhances reproducibility in chemistry by delivering applications that optimize chemicals, materials, and formulations in key areas such as pharmaceutical research, fine chemicals, and scientific education. DeepMatter also focuses on cheminformatics software that manages, stores, and retrieves chemical structures and reactions, facilitating synthesis planning and reaction prediction. Additionally, the company engages in the automatic extraction of scientific information from texts and images, contributing to the digitization of chemical space and discovery. Formerly known as Cronin Group Plc, the company rebranded in May 2018 and has been operational since its incorporation in 2006.

Exonate is a biotechnology company focused on developing small molecule drugs that modulate alternative messenger RNA splicing. It specializes in ophthalmology, with a primary focus on treating diabetic retinopathy and diabetic macular oedema (DMO), as well as wet age-related macular degeneration (wAMD). The company's lead program aims to provide superior efficacy through topical agents in preclinical models of wAMD.

Oppilotech is a London-based biotechnology company that develops antibacterial compounds with novel mechanisms of action to address drug-resistant organisms and advance the next generation of antibiotics. The company also offers a computational modeling platform that uses systems biology and machine learning to model cellular processes, identify viable drug targets, and enable researchers to simulate biology in order to discover new biology and therapeutic opportunities.

Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative tools and technologies for drug screening and safety testing. Established in 2016, the company offers a range of products including induced pluripotent stem cells, primary human and multispecies cells, and a comprehensive cell culture and analysis package. Stemnovate employs advanced devices such as micro physiological systems and microfluidic technologies to facilitate research and development. One of its notable projects, the "Liver on chip," focuses on liver toxicity testing and integrates cellular reprogramming, stem cell research, and organ-on-chip technology. The company also provides services in cell reprogramming, differentiation, and application development, catering to a diverse clientele that includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions.

Absynth Biologics Limited is a biotechnology company focused on discovering and developing vaccines and therapeutic antibodies aimed at preventing and treating bacterial infections. Founded in 2007 and based in Alderley Edge, United Kingdom, the company targets significant pathogens, including Staphylococcus aureus, Clostridium difficile, and Streptococcus pyogenes. Utilizing a platform that identifies novel protein antigen targets, Absynth Biologics employs a dual-action mechanism that combines direct antibacterial activity through antibody-mediated effects and the engagement of immune effector functions to eliminate bacteria. By characterizing specific proteins from these bacteria as immunological targets, the company aims to enhance patient immunity and address serious health threats associated with bacterial infections.

Founded in 2015, Heartfelt Technologies develops a telemonitoring system that uses optical sensors and AI to track foot volume changes in patients with heart failure. This data is analyzed to identify trends and provide timely alerts to healthcare providers, aiming to reduce hospital readmissions and improve patient care.

Founded in 2013, Talisman Therapeutics is a UK-based company dedicated to the discovery of treatments for Alzheimer's disease using human stem cell technology. It serves pharmaceutical companies, biotechs, and universities by offering advanced platforms for rapid drug target identification and validation.